Search Results

Displaying Results 1-2 of 2 "'LXRX'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Mar 03, 2026, 17:31 ET Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Eli Lilly (NYSE: LLY), Bayer AG (ETR: BAYN), Johnson and Johnson (NYSE: JNJ), Mitsubishi Tanabe Pharma Corporation, Lexicon Pharmaceuticals (NASDAQ: LXRX), Novo Nordisk (CPH: NOVO-B), and othersKey Chronic

More news about: DelveInsight Business Research, LLP

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Jan 20, 2026, 06:59 ET Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Viatris announced it had entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the U.S. and Europe. Inpefa is marketed by Lexicon Pharmaceuticals in the U.S. About Viatris

More news about: Viatris Inc.

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.